

Application Form and Essential Information

Innovation call: Improving the psoriasis patient holistic management and long-term well-being

Commissioning Organisation: Almirall

Deadline: 15/05/2026, 23:59 CET

Welcome to the registration process for the open innovation initiative **DermaSolve**, organised by Almirall S.A.

Through this form, you will have the opportunity to submit an innovative proposal that addresses one of the two proposed challenges (PsO or AD).

You must complete and attach this form to your application **by May 15th, 2026**. Remember that more detailed answers will give the jury a deeper understanding of your proposal.

Document Contents:

- 1.1. Essential Information and Legal Basis P. 2
- 1.2. Application Form P. 9

Important notes on submitting this application form:

- 1.3. You should complete the fields marked with a yellow background.
- 1.4. Your submission should contain only non-confidential information, and no data pertaining to individuals, particularly patients.
- 1.5. You confirm that there are no conflicts of interest and all applicable laws of your country and policies of your university/company have been adhered to.
- 1.6. If applicable, your technology transfer office or equivalent has been notified.

Once completed, please submit this form online:

- 1.7. Visit <https://almirallshare.com>.
- 1.8. Select the corresponding Innovation call and upload this application document.
- 1.9. Once uploaded you will be able to view the status of your submission and be notified with the date of an expected decision.

If you have any questions regarding the completion or submission of your application, or any other aspect of the Innovation call, please do not hesitate to reach out to helpdesk.dermasolve@opinno.com.

Thank you for participating in this innovation call! Much success and we look forward to hearing about your innovative proposal!

Essential Information and Legal Basis

I. Information about Almirall

Almirall S.A., with registered address at Ronda General Mitre, 151, 08022, Barcelona (Spain) and holding Tax Identification Number (NIF) A58869389, is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in bringing science and creativity together to improve skin health and innovate for a better future in patient care, and bring our innovative solutions to where they are needed most.

II. Our aim

As a pharmaceutical company dedicated to medical dermatology, **Almirall is committed to improving the lives of millions of people who suffer from skin diseases**. We understand that psoriasis (PsO) and atopic dermatitis (AD) are not only a physical condition, but also a source of emotional distress and social stigma for many patients. That is why we strive to provide innovative solutions that can offer holistic care and support for psoriasis and AD patients throughout their journey. We believe that by empowering patients to take control of their disease and integrating all the aspects of their well-being, we can make a positive difference in their life.

We are looking for **innovative solutions** to address some of the main challenges related to the **Psoriasis and Atopic Dermatitis Patient Journey**.

In previous research, we found that **patients need ongoing support and resources** to help them cope with everyday life and to **improve their quality of life** in the long term. In this innovation call, we focus on addressing the needs related to the **lack of empowerment** in managing their disease and the **lack of integration** of physical, social, mental, and other aspects related to the psoriasis or atopic dermatitis patient journey.

Below we describe the challenges and use cases we seek to solve:

Challenges for Psoriasis

Challenge:

How might we optimize psoriasis patient management by early, continuous, and tailored interventions to improve patients' long-term outcomes?

Use cases:

Use case 1: Early identification of patient needs and risk factors

Solutions we seek:

Mechanism that **alerts healthcare teams early to evolving patient needs or risks of progression**, and addresses the following points:

- **Lack of a standardized method to identify patients at risk of progressing.**
- HCPs have **limited consultation time** to explore lifestyle or emotional dimensions, often **relying only on visible symptoms**.
- **Patients with mild symptoms are not monitored closely**, despite potential risk.
- Delayed intervention leads to potentially **irreversible damage and reduced quality of life**.
- **Reactive follow-ups** only address problems once patients report dissatisfaction or reduced functioning.

Use case 2: Tailored management based on individual patient characteristics

Solutions we seek:

Personalized patient management solutions for healthcare teams may include **systems that analyze data from multiple sources, platforms that generate tailored recommendations for monitoring or support, or tools that facilitate adaptive, two-way communication**. The solution should address the following pains:

- **Patient management is based on clinical severity alone**, without considering their preferences, comorbidities, or behavioral and psychosocial information.
- **Follow-up is rigid** and not adapted to patient evolution.
- **Lack of digital tools to track symptoms, flares, or adherence in real time.**
- **Disconnection between data collected during consultations and patients' daily experience.**
- **Lack of tools to support shared decision-making.**
- **Patients feel unsupported because they do not receive timely support** when symptoms worsen or treatment fails.
- **Mental health burden is underestimated**, leaving patients without support for stress, anxiety, or emotional distress that can worsen disease activity and long-term outcomes.

Challenges for Atopic Dermatitis

Challenge:

How might we reduce the number of uncontrolled AD patients to deliver patient-centered care?

Use cases:

Use case 1: Shorten the time to effective treatment initiation

Solutions we seek:

Digital, behavioral, or systemic solutions that facilitate earlier recognition of uncontrolled AD patients, helping both patients and HCPs **act sooner and more effectively**, by addressing the following points:

- **Delay in first consultation to dermatologists** due to lack of recognition of symptoms and signs (chronic nature vs. acute condition).
- **Limited time and tools to accurately assess disease severity** in early stages, due to a lack of patient-reported outcomes and patient empowerment in treatment decisions.
- **Insufficient understanding of patient behaviors, flare triggers, and self-management practices before consultation.**
- **Inconsistent referral pathways** between primary care and dermatology.
- **Lack of digital or standardized tools** to detect early or worsening cases.

Use case 2: Healthcare system capacity improvement

Solutions we seek:

Digital ecosystems, service models, or data-sharing frameworks that optimize dermatologists' capacities to treat every patient with the desirable quality. The solution should address the following pains:

- **Patients feel lost between consultations**, without clear support or follow-up plans.
- **High patient volume with limited time** for education, follow-up, and holistic assessment.
- **Limited time and tools to accurately assess disease severity** in early stages, due to a lack of patient-reported outcomes and patient empowerment in treatment decisions.
- **Inefficient communication or data sharing** between primary and specialist care.
- **Difficulty prioritizing patients** based on disease control status.
- **Lack of scalable models to provide continuous support** between visits.

III. The innovative projects and solutions requirements

The solutions must have at least a **Technology Readiness Level (TRL) 2**, corresponding to having a technology concept and/or application formulated and must be at a development level below **TRL 5**, which implies proven technology in a relevant environment.

A **Participant Toolkit** is available on the challenge's webpage to help candidates prepare their applications. **Finalists will also receive a guide** on the format, length and information expected for the final pitch.

TECHNOLOGY READINESS LEVEL (TRL)

| | | |
|-------------|---|---|
| DEVELOPMENT | 9 | ACTUAL SYSTEM PROVEN IN OPERATIONAL ENVIRONMENT |
| DEVELOPMENT | 8 | SYSTEM COMPLETE AND QUALIFIED |
| DEVELOPMENT | 7 | SYSTEM PROTOTYPE DEMONSTRATION IN OPERATIONAL ENVIRONMENT |
| DEVELOPMENT | 6 | TECHNOLOGY DEMONSTRATED IN RELEVANT ENVIRONMENT |
| DEVELOPMENT | 5 | TECHNOLOGY VALIDATED IN RELEVANT ENVIRONMENT |
| DEVELOPMENT | 4 | TECHNOLOGY VALIDATED IN LAB |
| RESEARCH | 3 | EXPERIMENTAL PROOF OF CONCEPT |
| RESEARCH | 2 | TECHNOLOGY CONCEPT FORMULATED |
| RESEARCH | 1 | BASIC PRINCIPLES OBSERVED |

The definition criteria for each of the maturity levels are as follows:

- **TRL 2:** Initial practical applications are identified. The potential of a material or process to solve a problem, satisfy a need, or find an application is confirmed. Applications are speculative, and there may be no proof or detailed analysis to support the assumptions. Examples are still limited to analytic studies. Supporting information includes publications or other references that outline the application being considered and that provide analysis to support the concept. The step up from TRL 1 to TRL 2 moves the ideas from basic to applied research.
- **TRL 3:** Applied research advances and early-stage development begin. Studies and laboratory measurements validate analytical predictions of separate elements of the technology. Its components are validated, but there is no strong attempt to integrate the components into a complete system. Modeling and simulation may be used to complement physical experiments.
- **TRL 4:** Design, development, and lab testing of components/processes. The basic technological components are integrated to establish that the pieces will work together. This is relatively "low fidelity" compared with the eventual system. Supporting information includes the results of the integrated experiments and estimates of how the experimental components and experimental test results differ from the expected system performance goals.
- **TRL 5:** System Component and/or process validation is achieved in a relevant environment. The basic technological components are integrated for the system configuration to match the final application in almost all respects. Supporting information includes laboratory scale testing results, analysis of the differences between the laboratory and eventual operating system/environment, and analysis of the meaning of the experimental results for the eventual operating system/environment. The major difference between TRL 4 and 5 is the increase in the fidelity of the system and environment to the actual application. The system tested is almost prototypical.

IV. Eligibility

This call is open to healthcare organizations (HCOs), including universities, healthcare centers, or research centers. This call encompasses medical disciplines related to psoriasis and AD, emphasizing a holistic approach beyond Dermatology.

Participants must be working in one of the regions where this Initiative is being launched (**Spain, Italy, Portugal, Germany, Switzerland, Austria, France, UK, Poland, Slovakia, Denmark**,

Norway, Sweden, Belgium, the Netherlands, and Luxembourg). Proposals may be excluded from participation in case a possible conflict of interest is identified with the team, its partners, or the legal entity they belong to. A conflict of interest is a situation where a person's personal, financial, or professional interests could compromise—or appear to compromise—their ability to act objectively and in the best interest of their role or responsibilities. Examples of a conflict of interest:

- Kinship Relationships: The individual or related parties have kinship relationships up to the third degree with any employee, director, or representative of Almirall.
- Financial Interests: The individual or related parties hold, directly or indirectly, a significant contribution in any company within Almirall, such as stocks or shares.

V. The Initiative will be subject to Spanish Law as set below. Participants in the initiative acknowledge that they are not acting as consumers and therefore waive any right to apply any other law.

VI. Timing

The submission period **is from January 19th, 2026, to May 15th, 2026**, both inclusive.

All the initial information provided under the proposal should be non-confidential (for Almirall internal use only, for the management of the challenge).

Almirall reserves the right to suspend, extend and/or modify the deadline for submission of applications, as long as there is a justified cause and it does not harm the rights of the Participants up to that point, in which case it will be communicated in due time.

VII. Submission process

- The first step is for you to create an account in AlmirallShare Innovation platform (<https://almirallshare.com>), which is a secure site to store and manage your proposals.
- (Optional, but recommended) Download, read, and work on the toolkit to strengthen and structure your proposal.
- Please include an outline of your proposal and a detailed description of your proposal by completing and uploading the Submission Form attached to the registration form.
- Submissions will be handled following all applicable local compliance rules.

VIII. Evaluation Criteria and Proposal Examination

- Once the submission period ends, your proposal will be first evaluated by a Jury selected and contracted by Almirall, and composed of:
 - 2 health innovation experts,
 - 7 healthcare professionals.
- The Jury will review your proposal in line with the following **evaluation criteria**:
 - **Impact on the patient (30%)**: Capacity to improve the patient's quality of life and cover as many patient journey stages and patient needs as possible.
 - **Impact on the healthcare ecosystem (20%)**: Ability to provide benefit to stakeholders such as HCPs, health institutions, or caregivers by facilitating the medical visit, promoting the sustainability of the system...
 - **Innovation (20%)**: Capability to differentiate from other projects and add value through

the new application of technologies, methodologies, or approaches.

- **Scalability in the healthcare ecosystem (15%)**: Competence to integrate into healthcare processes, with the potential for implementation at the national level, while ensuring compliance with required regulatory frameworks.
- **Multidisciplinary Team (10%)**: Profiles of the team will provide multidisciplinary skills to the team, as well as dedicate the necessary time for project development and implementation.
- **Personalization (5%)**: The ideal solution will adapt to the individual needs of each user, resulting in the creation of personalized experiences and information.
- Following the initial evaluation, the Jury will assess and rank the submitted proposals **within 6 to 8 weeks** after the submission deadline. Once the Jury has completed its ranking, 2 Patient Organizations will review the ranked proposals and select up to **6 finalists; 3 for the Psoriasis (PsO) Challenge and 3 for the Atopic Dermatitis (AD) Challenge** (hereinafter referred to as the "Finalists"). Regardless of whether your proposal is selected among the six Finalists, you will receive a written notification of the decision from Almirall.

All the Finalists will participate in a **Pitch Day (1 person per team)**. On the Pitch Day, each of the Finalists will have a time slot in which to describe to the Jury and two representatives of Patient Organizations (one on AD and another one on PsO) their solution and their pilot proposal for further development. The Jury and the Patient Organizations will cast one vote per challenge to select which of the Finalists will become the Selected Proposals (hereinafter, the 'Selected Proposals')

If your proposal is one of the Selected Proposals of the program, we will reach out to you to initiate the process of the grant agreement to support your solution with the funding provided.

IX. Finalists

Almirall reserves the right to establish **partnerships** with any of the **Finalists**' solutions within 6 months after the end of the programme. In accordance with the above, the Finalists expressly agree not to disclose or transmit their projects to third parties, including companies that may be competitors of Almirall, nor commercially exploit them with entities other than Almirall during this period. Notwithstanding the above, Finalists may be entitled to disclose and/or transfer their projects to third parties, subject to written authorization granted by Almirall.

X. Selected Proposals

- The **2 Selected Proposals** with highest scoring will be communicated within Almirall communication plan. In addition, they will receive a commitment from Almirall for the funding of up to **50.000 €** gross for the development of the Testing Plan presented at DermaSolve innovation call.
- The funding for the Testing Plan from Almirall to the selected candidates will be agreed on separate terms from this Legal Basis. For the avoidance of doubt, the funds will be used in full to finance the project.
- **Intellectual property rights** remain with the applicant. You will retain ownership of any intellectual property you may bring or develop. The option for Almirall to license or purchase (the "Option") any right, title, or interest in the Selectee's Foreground IP related to the project might be negotiated between both parties.

You can submit your questions to helpdesk.dermasolve@opinno.com Almirall-designated contact person will help you.

XI. Data Protection

By submitting your proposal you agree for Almirall to process your personal data to manage the open challenge in accordance with the Privacy Policy available at <https://almirallshare.com/>

Governing law and dispute resolution.

This Initiative shall be governed and construed in accordance with the laws of Spain. Any dispute or difference arising out of or in connection with this Legal Basis shall be settled by the Courts and Tribunals of the city of Barcelona, with express renouncing and waiving of any rights to any other jurisdiction that may correspond to any of the Parties.

Almirall, Science, and you.

AlmirallShare Team

1. Application form to be completed by candidates:

Please fill out all the fields marked with an (*).

General information

| | |
|--|--|
| Your Name * | |
| Your Surname * | |
| Your email * | |
| Name of your organization * | |
| Country* | |
| Type of your organization * | |
| How did you hear about Almirall's initiative * | |
| Website / social media of the proposal (if applicable) | |

Has your proposal received any awards or recognition? If so, what type of recognition was it, when was it received and who awarded it (maximum 1200 characters). *

Example: Yes, the proposal won the "Best Digital Health Innovation Award" at the 2022 Global HealthTech Summit. This award recognized the project's innovative approach to improving patient outcomes through AI-driven diagnostics. The summit took place in Barcelona and was hosted by the European HealthTech Network.

Has the proposal received any funding from inception? If so, please specify the type and amount (maximum 1200 characters). *

Example: Yes, the project received \$200,000 in seed funding in 2021 from HealthVentures, a biotech-focused venture capital firm. Additionally, it secured a \$50,000 government innovation grant in 2022 to support early-stage prototyping.

About the candidate proposal

Q1. To which challenge and use case does your proposal provide an answer? *

- a. PsO challenge, use case 1: Early identification of patient needs and risk factors.
- b. PsO challenge, use case 2: Tailored management based on individual patient characteristics.
- c. AD challenge, use case 1: Shortened time to biologic therapy initiation.
- d. AD challenge, use case 2: Healthcare system capacity improvement.

Q2. Briefly describe your proposal, how it addresses the challenge posed, and the technology, functionalities, and/or methodology used and/or developed. (maximum 1800 characters).*

Example:

Our proposal is an AI-powered mobile application that provides personalized lifestyle and treatment recommendations for psoriasis patients. It combines patient-reported outcomes, wearable device data, and AI analytics to offer real-time insights on triggers, treatment efficacy, and stress management.

Value proposition

Q3. What is the value proposition of your proposal? What needs does it address, and what benefits does it provide to patients, carers, and healthcare professionals? (maximum 2400 characters).*

Example:

The value proposition of our project is to empower psoriasis patients with personalized, actionable insights, improving adherence to treatments and overall quality of life. It benefits caregivers by offering tools to monitor patient progress and supports healthcare professionals by providing data-driven reports for informed decision-making.

Q4. How does your proposal differ from other solutions already on the market? (maximum 1200 characters). *

Example:

Our project combines real-time data from wearable devices with an AI algorithm tailored specifically to psoriasis. Its focus on holistic health, including mental well-being and lifestyle adjustments, sets it apart from conventional treatment-tracking apps.

Q5. How will patients and/or other targeted stakeholders use your proposal? Describe how it integrates into their daily lives, its degree of accessibility and whether any training is required to use it (maximum 1200 characters). *

Example:

Patients will use the app daily to log symptoms, triggers, and treatment responses. The app is accessible via smartphone and integrates with popular wearable devices for seamless data collection. Minimal training is required, and in-app tutorials are provided to guide users.

Q6. Does your proposal have, or will it have, the ability to be personalized according to the individual needs of each user? If so, in what way? (maximum 1200 characters)

Example:

Yes, the app adapts its content based on user profiles. For example, younger users receive simplified language and gamified elements, while older users can access detailed medical explanations and larger text options for accessibility.

Implementation and scalability

What stage of development is the proposed solution in? Which best describes the technology? *
[Only one option is ticked].

1. Basic principles observed and reported.
2. Practical applications of the observed principles formulated.
3. An analytical and experimental proof of concept has been carried out.
4. Laboratory validated technology or components.
5. Technology validated at component level in a relevant environment (clinical simulations, pre-clinical trials or controlled environments)
6. Proven technology in a relevant environment
7. Demonstration of prototypes in operational environments (clinical trials or hospital implementation)
8. Complete and qualified system to be used in real conditions.
9. It has been successfully tested under real conditions and is in use.

Q7. Based on the indicated maturity level, briefly explain the development stage of your proposal. (maximum 1800 characters). *

Example:

The proposal is at a prototype stage, with clinical validation completed in partnership with Barcelona Health Institute. A pilot test involving 50 patients showed a 30% improvement in symptom management and a 20% increase in treatment adherence

Q8. Does the proposal have intellectual property, or is it in the process of obtaining it? (maximum 300 characters). *

Example:

Yes, the project has filed a patent application for its proprietary AI algorithm. The patent is currently under review and expected to be granted by Q3 2025.

Q9. Can your proposal be integrated into the operational, technical, regulatory, and IT systems used by healthcare institutions? Is the proposal scalable? If so, please explain. (maximum 1200 characters).

Example:

Yes, our proposal integrates seamlessly into healthcare systems by using interoperable standards like HL7 FHIR for compatibility with EHR platforms. It complies with HIPAA regulations. The cloud-based infrastructure supports scalability, allowing deployment across multiple institutions, while its modular design adapts to diverse operational and IT environments.

About the team

Q10. Team description. Describe briefly the number of team members, the roles of the main team members, and their involvement in the proposal (maximum 1800 characters). *

Example: The team consists of 5 members:

- *Project Lead (Dr. Name Surname): Overseeing project direction and stakeholder engagement.*
- *Chief Technology Officer (Name Surname): Responsible for technology development and integration.*
- *Medical Advisor (Dr. Name Surname): Providing clinical insights and ensuring compliance with medical standards.*
- *Data Scientist (Name Surname): Developing AI algorithms for personalized patient monitoring.*
- *Patient Advocate (Name Surname): Representing patient perspectives and needs.*

Q11. Does any member of the candidate team have a family relationship with Almirall employees or financial interests (stocks or shares) with Almirall? If so, please explain the details (*maximum 600 characters*).*

Example: No, none of the team members have any family relationships with Almirall employees or hold financial interests such as stocks or shares in the company.

Please make sure to click the **DOWNLOAD** button on your browser before sending the form. Select the “**with your changes**” option

